Business Context and Reporting Period
Calidi Biotherapeutics, Inc. (CLDI), a Delaware corporation and emerging growth company, filed this Form 8-K on May 6, 2026. The filing reports the entry into a material definitive agreement involving the issuance of unregistered equity securities.
Key Financial Metrics and Transaction Details
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, or margins. The primary financial data relates to a specific capital transaction:
- Instrument Issued: Warrant to purchase up to 17,391,304 shares of common stock.
- Exercise Price: $0.23 per share.
- First Exercisable Date: September 8, 2026.
- Contingent Issuance: The warrant holder may agree to acquire up to $4.0 million of common stock prior to July 8, 2026, subject to vesting conditions.
- Investor Type: Accredited investor in a private placement.
Material Changes Versus Prior Period
The filing does not provide comparative financial data or discuss changes in operating metrics versus prior periods. The material change is the creation of a new warrant instrument and the potential for future equity issuance contingent on the investor's election to purchase up to $4.0 million of stock.
Guidance, Outlook, and Risks
Management Commentary: The Company states that neither the holder nor the Company has an obligation to consummate the potential $4.0 million stock issuance. The warrant vests in proportion to any such issuances that are consummated.
Risks and Contingencies:
- Resale Restrictions: Shares issued upon exercise of the warrant may not be re-offered or sold in the United States absent an effective registration statement or an applicable exemption.
- Uncertainty of Issuance: The vesting of the warrant and the issuance of additional shares are contingent on future agreements between the Company and the investor, which are not guaranteed.
Important Facts for Investor Verification
- Verify the full terms of the warrant in Exhibit 4.1, as the filing summary is qualified by reference to the full text.
- Confirm whether the Company intends to register the shares issuable upon exercise or if the investor will rely on exemptions for resale.
- Monitor the period between May 6, 2026, and July 8, 2026, for any announcements regarding the potential $4.0 million stock purchase.
- Note that the filing does not disclose the Company's current cash position or liquidity status.